

Strategic Allocation Framework Progress

Dr. Jonathan Thomas, *President and CEO*


September 24, 2026

Our Mission

To accelerate world-class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and the world

CIRM Strategic Allocation Framework

Translating dollars entrusted to CIRM into benefits to Californians



Accelerating Discovery & Translation

Goals

Goal 1: Catalyze at least 4 novel targets and biomarkers

"First step toward a cure: Finding the target"

\$8.5B



Goal 2: Accelerate 5-8 technologies

"Creating the technology that moves medicine forward"

Accelerating Discovery & Translation

Progress

- Revamped DISC4 & DISC5 research programs are drawing high interest from applicants
- About to launch a new program that will help our awardees share data and move faster
- Data Sharing and Management Plans in place across all CIRM R&D programs
- We are evaluating technologies that have come out of our translational awards (TRAN, PDEV, CLIN1)
- New Discovery awards coming to the Board in December (EDEV) and technology awards launching next year (TDEV)

Cell & Gene Therapy Approvals

Goals

Goal 3: Advance 4-7 rare disease projects to BLA

"Fueling cures – not just hope – for millions living with rare disease"

\$8.5B



Goal 4: Propel therapies to late-stage trials

"Accelerating proven science toward FDA approval"

Cell & Gene Therapy Approvals

Progress

- Launched the \$100M RAPID program to accelerate therapies for rare disease
- 1 BLA approved thus far (Kresladi)
- 10 additional programs closing in or en route
- Consolidated six preclinical programs into one (PDEV)
- Rosa to describe CLIN2 portfolio next

Accessibility & Affordability

Goal

Goal 5: Ensure A&A strategy

"The true measure of progress is who it reaches"



Accessibility & Affordability

Progress

- Actively implementing CIRM's Access & Affordability strategy
- The Clinical Network Northern California site to be voted on today
- Patient Support Program covers net patient expenses
- Stage appropriate access plans are now mandatory
- Rocket Therapeutics access plan up for approval this week
- Actively engaging in discussions with various stakeholders on access, reimbursement and payment models

Workforce Development

Goal

Goal 6: Bolster California's workforce

"Empowering Californians with skills to develop life-changing therapies"

\$8.5B



Workforce Development

Progress

- Each of our four programs are highly popular, with applicant numbers increasing every year
- Bridges outcome data shows sustained interest in STEM
- Awards for the revamped Bridges/COMPASS Umbrella (EDUC8) approved today
- Supplemental funding for Research Scholars (EDUC4) later on today's agenda
- New emphasis on technical skills required in today's regenerative medicine ecosystem